Skip to content
Viagra LabsViagra Labs
Search
MenuSearch
Product image unavailable

Helleva (lodenafil)

Helleva is the original lodenafil carbonate brand from Cristália in Brazil. Learn what lodenafil is and how it was studied.

Active ingredient
Lodenafil
Form
Tablet
Company
Cristália Produtos Químicos Farmacêuticos (Brazil)

Helleva is the brand name of lodenafil carbonate, a PDE5 inhibitor developed and marketed by Cristália in Brazil.

An unusual design

Lodenafil carbonate is a pair of lodenafil molecules joined together. The body splits it into two molecules of the active drug, a design intended to improve absorption.

Evidence

A Brazilian phase III trial in 350 men compared 40 mg and 80 mg with placebo and found improved erectile function scores, with headache, flushing, rhinitis and indigestion among the side effects. Lodenafil is not authorized in the EU, UK or US.

Product record

Company
Cristália Produtos Químicos Farmacêuticos (Brazil)
Strengths
Lodenafil carbonate 40 and 80 mg (phase III trial doses)
Market
Brazil (Cristália)
Treatment area
Erectile dysfunction (ED)
Information checked
3 October 2026

Published research describes this product; it is not authorized in the EU, UK or US.

About lodenafil

Lodenafil carbonate is a PDE5 inhibitor developed in Brazil. The body splits each molecule into two molecules of active lodenafil. It is not authorized in the EU, UK or US.

Using a PDE5 inhibitor safely

Never take a PDE5 inhibitor with nitrates, recreational nitrites (“poppers”) or riociguat, and do not combine two ED medicines. Seek urgent medical help for chest pain, an erection lasting more than four hours, or sudden loss of vision or hearing.

Common side effects include headache, flushing, indigestion and a blocked nose.

Sources

Checked .

  1. The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts (J Clin Med, 2020) — Europe PMC
  2. Efficacy and tolerability of lodenafil carbonate: a phase III clinical trial (J Sex Med, 2010) — Europe PMC
  3. Pharmacological characterization of lodenafil carbonate (Eur J Pharmacol, 2008) — Europe PMC